NSRX Stock — Nasus Pharma Ltd.: Cash, EV, Pipeline

Share price

$3.53

Market cap

$41.3M

Cash

$1.2M

Enterprise value

$40.1M

Balance sheet

Cash	$1.2M
Debt	$0.0M
Net cash	$1.2M
Enterprise value	$40.1M
Basic shares	11.7M shares
Fully diluted shares	9.2M shares
Fully diluted market cap	$32.4M
Cash per share	$0.11

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading NSRX daily closes…

Loading price history…

Pipeline assets

NS002

Phase 2 · Active Modality: intranasal epinephrine powder nasal spray

Target adrenergic receptors

Indications

Anaphylaxis/severe allergic reactions (vs EpiPen IM injection) (Phase 2)

Catalysts

— Q3 2026
— Q4 2026

Status note Lead candidate (intranasal epinephrine). Completed 12-patient pilot and 12-patient Phase 2 (PK in line with IM epinephrine). Additional Phase 2 in Canada launched Nov 2025 (50 healthy adults with allergic rhinitis vs EpiPen); additional Phase 2 evaluating self-administration planned Q2 2026; IND not yet filed.

NS001

Preclinical · Active Modality: intranasal naloxone

Target opioid receptor

Indications

Not named in excerpts (Preclinical)

Status note Intranasal Naloxone development paused; company planning to pursue partnering opportunities for this program.

intranasal atropine

Preclinical · Active Modality: intranasal atropine powder nasal spray

Indications

Organophosphate poisoning (Preclinical)

Status note Filing names intranasal atropine powder nasal spray for organophosphate poisoning as a program using the company's platform technology (tested with preclinical and in-vitro molecules).

intranasal ondansetron

Preclinical · Active Modality: intranasal ondansetron powder nasal spray

Indications

Intractable vomiting (Preclinical)

Status note Filing names intranasal ondansetron powder nasal spray for intractable vomiting as a program using the company's platform technology.

Per-asset detail extracted from the 20-F filed 2026-03-25. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Epinephrine 4mg nasal powder spray
Lead indication	Anaphylaxis Food
Lead phase	Phase 2/3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07045701	Phase 2/3	Enrolling by invitation	Sponsor	Nasus Pharma	—	Anaphylaxis Food	—
NCT07228325	Phase 1/2	Enrolling by invitation	Sponsor	Nasus Pharma	—	Anaphylaxis; Allergy	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Nasus Pharma on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

NSRX — Nasus Pharma Ltd.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials